M&A / Deals Samsung Biologics to acquire PolyPeptide in $1.81bn cash deal Pharmaceutical Business ReviewThe proposed offer is set at SFr44.31 per share for 100% of PolyPeptide's fully diluted share capital, excluding treasury shares.Read full story pharminent July 20, 2026 (Last updated: July 23, 2026) Pharmaceutical Business Review The proposed offer is set at SFr44.31 per share for 100% of PolyPeptide’s fully diluted share capital, excluding treasury shares. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA Converts Novartis’ Fabhalta to Full Approval in IgA NephropathyNext: Lundbeck preps for key bexicaserin data around year-end Related Stories M&A / Deals Repligen builds in cell therapy with $1.5bn BioLife takeover pharminent July 22, 2026 M&A / Deals Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics pharminent July 20, 2026 M&A / Deals Lilly enters psychedelic realm through $2.8bn AtaiBeckley takeover pharminent July 16, 2026
